logo
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

Yahoo30-04-2025

RANCHO CUCAMONGA, CA / / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.
The call can also be accessed on the Investors page on the Company's website www.amphastar.com. The webcast replay of the call will be available on our Company website within 24 hours after the end of the live conference call.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Forward Looking Statements
All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits BAQSIMI®, including its potential for continued revenue growth, the strategic trajectory of and market for our product pipeline, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025 and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact:
Bill PetersChief Financial Officer(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Nick Wodeshick from The Alternatives Channel Announces Publication Titled - CPSL: The ETF Seeking 100% Downside Protection in All Seasons
Nick Wodeshick from The Alternatives Channel Announces Publication Titled - CPSL: The ETF Seeking 100% Downside Protection in All Seasons

Yahoo

time33 minutes ago

  • Yahoo

Nick Wodeshick from The Alternatives Channel Announces Publication Titled - CPSL: The ETF Seeking 100% Downside Protection in All Seasons

New York, New York--(Newsfile Corp. - June 10, 2025) - Nick Wodeshick is excited to announce the publication of this recent article "CPSL: The ETF Seeking 100% Downside Protection in All Seasons" on the VettaFi Alternatives Channel. This article explores how the Calamos Laddered S&P 500® Structured Alt Protection ETF (CPSL) may offer investors the potential for both upside participation and 100% downside protection in an uncertain market environment. CPSL: The ETF Seeking 100% Downside Protection in All Seasons With the market outlook uncertain, financial advisors may want to build a portfolio strategy prepared for both good and bad news. This is where the Calamos suite of Structured Protection ETFs® could come into play. Given the shifting market conditions, the Calamos Laddered S&P 500® Structured Alt Protection ETF (CPSL) offers an interesting use case. A fund of funds, CPSL equally allocates across 12 monthly Calamos S&P 500® Structured Alt Protection ETFs®, whose outcome periods are staggered across different months. These underlying ETFs blend capped equity upside with downside risk mitigation. After paying fees and expenses, these funds protect against 100% of losses incurred over their respective outcome periods. Read the full article here: About Calamos Investments As a proven provider of alternative ETF strategies, Calamos Investments offers a wide selection of ETFs listed in the U.S. In total, these funds represent over $800 million in assets under management, according to FactSet data. About VettaFi VettaFi is a leading provider of data-driven insights and specialized services for asset managers and investors, bringing together a wealth of expertise to support client success. At the core of VettaFi is a commitment to fostering strong relationships and delivering innovative solutions that help clients engage, grow, and thrive in an increasingly complex financial landscape. For more information about VettaFi, please visit Media Contact: help@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AI Code Review Pioneer CodeRabbit Recognized in Redpoint's InfraRed 100
AI Code Review Pioneer CodeRabbit Recognized in Redpoint's InfraRed 100

Yahoo

time33 minutes ago

  • Yahoo

AI Code Review Pioneer CodeRabbit Recognized in Redpoint's InfraRed 100

InfraRed Report Shows Cloud Infrastructure Powers Virtually All Software WALNUT CREEK, Calif., June 10, 2025--(BUSINESS WIRE)--CodeRabbit, the most advanced AI code review platform, today announced its inclusion on the Redpoint InfraRed 100. This prestigious list highlights the 100 up-and-coming private companies in Cloud Infrastructure, showcasing the future leaders set to revolutionize the market. CodeRabbit integrates foundational gen-AI models with multiple data sources that enhance the code context, leading to higher quality reviews, cutting down code review time and bugs in half. CodeRabbit's AI code reviews have been rapidly adopted by customers including The Linux Foundation, Groupon, Chegg, Trivago, and many more. Redpoint Ventures, a top-tier venture capital firm with a diverse portfolio including companies such as Snowflake, Twilio, Looker, Nextdoor, Ramp, Stripe, Nubank, HashiCorp, Netflix, Hims, and more, launched this list in 2023 to showcase the exceptional builders in the industry who are creating industry-transforming companies. To commemorate this achievement, CodeRabbit's co-founder and CEO Harjot Gill will join Redpoint at Nasdaq with other InfraRed 100 leaders to discuss the evolving landscape of cloud infrastructure. "We are honored to be recognized in the InfraRed 100, especially alongside such a distinguished group of cloud infrastructure companies. We founded CodeRabbit with the mission to transform code reviews with AI to help developers automate the tedious parts of software development. We believe that AI, when augmented with appropriate context and implemented with the right guardrails will identify defects that are hard to catch in manual reviews, leading to fewer bugs and faster release cycles," said Gill. "We thank the team at Redpoint for this recognition and congratulate all the companies on the list." For the complete list of companies included on this year's InfraRed 100 list and to read the full InfraRed industry report, click here. About CodeRabbit CodeRabbit is the pioneer of the AI code review category, evolving the historically manual and low-context review process into a more automated, context-aware workflow that's compatible with today's highly dynamic CI/CD pipeline. CodeRabbit enables engineering organizations that use code-gen agents to generate code at a fast pace to identify code quality issues before production, reducing code review cycles and allowing developers to reclaim valuable time. Headquartered in Walnut Creek, California, and funded by CRV, Flex Capital, and Engineering Capital, CodeRabbit is on a mission to transform code quality, security, and developer productivity with AI. Try CodeRabbit free at: About Redpoint Ventures: Redpoint has partnered with visionary founders to create new markets and redefine existing ones since 1999. We invest in startups across the seed, early and growth phases, and we're proud to have backed over 615 companies—including Snowflake, Looker, Kustomer, Twilio, 2U, DraftKings, Duo Security, HashiCorp, Stripe, Guild, HomeAway, Heroku, Netflix, and Sonos—with 183 IPOs and M+A exits. Redpoint manages $8.0 billion across multiple funds. For more information visit: View source version on Contacts Heather FitzsimmonsMindshare PR650-279-4360heather@

1981 Honda Accord SE Pushes Honda into $10K Territory
1981 Honda Accord SE Pushes Honda into $10K Territory

Car and Driver

time35 minutes ago

  • Car and Driver

1981 Honda Accord SE Pushes Honda into $10K Territory

From the March 1981 issue of Car and Driver. The rep for the American Honda Motor Company, Inc., when he handed over the keys to the fresh-off-the-boat 1981 Accord SE, lowered his voice to a conspiratorial tone and said, "This is just a little testing of the waters—to see if Honda can sell in the BMW price range." "SE," in case you haven't heard, stands for "Special Edition," and those words will ap­pear in delicate chrome script on the Glacier Grey Metallic flanks of a mere 3000 Accord four-doors this year. These specially anoint­ed sedans will carry every option in the Hon­da book, including power windows, power steering, power brakes, Michelin radials, four-speaker AM/FM/cassette stereo, and air conditioning. Beyond that extends a long list of fitments that are not in the Honda book­—at least they weren't until now—including power antenna, folding rear-seat armrest, al­loy wheels, special gray deep-pile carpeting, and genuine Connolly leather on the seats. This, you might conclude, is intended to be one plush little unit. View Photos Patrick Bedard | Car and Driver Hearing all of this, and knowing how crazy car prices have become in recent months, we ventured a tentative "How much?" "Only $9950," was the answer. Aargh! A $10,000 Honda! "That's the five-speed. The automatic is 10,200," he said. How can a Honda cost $10,000? You guys keep it simple, right? You're the company that removed the stigma from small-car own­ership. It was okay to have a Honda. Rich people bought them. But this Special Edition is a cop-out. Any company can be in the stig­ma-free-small-car business if it charges a lot of money. "Yeah, but the SE has all the stuff. You take your base Accord at $7435, add $600 for air, $500 for the digital cassette radio. Al­ready it's $8500. This is a great deal." View Photos Patrick Bedard | Car and Driver Well, folks, maybe it is. But looking at the parts list, we come away with the idea that a few bits of trim add 1500 bucks to the price. Of a Honda. It wasn't so long ago that you could get a whole Honda for that money. For the full several hundred miles of our evaluation drive, this five-digit price kept nagging at the old editorial sense of value. This is a $10,000 Honda? And if it is, then what must rutabagas be going for down at the Hy-Vee? Certainly the Special Edition gives every indication of being a Honda. It has all those little idiosyncrasies we've grown accustomed to: the soft chattering when you engage the clutch and the gentle bucking of the engine when you ask it to accelerate from low revs. View Photos Patrick Bedard | Car and Driver But the old Honda charm is there, too. The engine climbs happily to the redline. The body doesn't creak and groan. The inte­rior is perfectly assembled—nary a loose thread or smear of adhesive to catch the crit­ical eye. And the luxury touches are so tastefully and confidently done. The trunk is thickly carpeted and fitted with small bins on the sides to hold minor objects that you don't want to roll around. The interior is a light dove gray, very popular at Ford a few years back but still fashionable enough. And the seats really are leather, exuding just a trace of the aroma that Connolly also imparts to every Rolls-Royce and Jaguar. Moreover, the Special Edition seems to work better than any Accord we've ever driv­en. The usually flaccid shock absorbers seem a bit tauter. The shape of the seat is correct, its depression for your butt back where it be­longs now, rather than halfway forward in typical Japanese fashion. The power steering isn't as numb as it used to be. The direction­al stability is better. The car more graceful. Its mood more, well, BMW-like. Of course, we car critics can still find faults. The power-window controls are big and bulky, looking very much like the tack­-ons they are. The stereo sounds as though it has K-mart speakers. And the radio itself has so many tiny buttons, with such small de­scriptions of what they do, that you practical­ly have to pull over to the side of the road just to change from AM to FM. But it'll sure do some tricks, this radio, and the car around it is such a jewel that maybe $10,000 really is fair. Certainly there's noth­ing else on the market with similar quality, luxury, and efficiency for ten grand. View Photos Patrick Bedard | Car and Driver Just when we had convinced ourselves that there is value in a $10,000 Honda, we saw a dealer ad in the classified section of the New York Times brazenly offering an SE five-speed for $13,950. Apparently while the American Honda Motor Company is merely testing the BMW waters, dealers are jumping right in. They may be avaricious and unconsciona­ble opportunists, the car dealers of this coun­try, but one thing you have to give them: they do know what cars are worth. Specifications Specifications 1981 Honda Accord Vehicle Type: front-engine, front-wheel-drive, 4-passenger, 4-door sedan PRICE Base/As-Tested: $9950/$9950 ENGINE SOHC inline-4, iron block and aluminum head Displacement: 107 in3, 1750 cm3 Power: 75 hp @ 4500 rpm TRANSMISSION 5-speed manual DIMENSIONS Wheelbase: 93.7 in Length: 171.9 in Curb Weight (C/D est): 2250 lb EPA FUEL ECONOMY City: 27 mpg

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store